Anti-Rheumatic Drugs - G20

In 2024, the revenue in the Anti-Rheumatic Drugs market is forecasted to reach a staggering US$45.93bn.
Looking ahead, the market is expected to exhibit a steady growth rate of -0.72% annually from 2024 to 2029, leading to a market volume of US$44.30bn by 2029.
When compared globally, it is worth noting that United States will generate the highest revenue in this market, with an estimated US$34,700.00m in 2024.
The United States, being a member of the G20, holds a significant position in the Anti-Rheumatic Drugs market.
In the G20 country of Germany, there is a growing trend towards the use of biologic anti-rheumatic drugs due to their effectiveness in managing symptoms and improving quality of life for patients with rheumatoid arthritis.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in G20 countries has been on the rise in recent years due to the increasing prevalence of rheumatoid arthritis and other autoimmune diseases.

Customer preferences: Patients suffering from rheumatoid arthritis and other autoimmune diseases are increasingly seeking more effective and safer treatment options. This has led to a growing demand for biologic drugs that target specific components of the immune system, such as tumor necrosis factor (TNF) inhibitors and interleukin inhibitors. Patients also prefer drugs that have fewer side effects and are more convenient to administer, such as oral medications or self-administered injections.

Trends in the market: In the United States, the Anti-Rheumatic Drugs market has been dominated by biologic drugs, which accounted for the majority of sales in recent years. However, the market share of biosimilars is expected to increase in the coming years due to the expiration of patents for several biologic drugs. In Europe, biosimilars have already gained a significant market share due to favorable pricing policies and the availability of a regulatory pathway for their approval. In Japan, the market for Anti-Rheumatic Drugs has been growing rapidly due to the aging population and the increasing prevalence of rheumatoid arthritis.

Local special circumstances: In China, the market for Anti-Rheumatic Drugs has been growing rapidly due to the increasing prevalence of rheumatoid arthritis and the government's efforts to improve access to healthcare. However, the market is highly fragmented, with many local manufacturers competing with multinational companies. In Brazil, the market for Anti-Rheumatic Drugs has been growing due to the increasing prevalence of rheumatoid arthritis and the government's efforts to improve access to healthcare. However, the market is highly regulated, and the approval process for new drugs can be lengthy and complex.

Underlying macroeconomic factors: The increasing prevalence of rheumatoid arthritis and other autoimmune diseases is a key driver of the Anti-Rheumatic Drugs market in G20 countries. The aging population and changing lifestyles, such as reduced physical activity and increased stress, are contributing to the rising incidence of these diseases. In addition, the increasing availability of healthcare services and the growing awareness of these diseases are driving demand for Anti-Rheumatic Drugs. The approval and pricing policies of governments and regulatory agencies are also important factors that affect the market dynamics in different countries.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.